NCT00975507View on ClinicalTrials.gov

ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

March 31, 1998

Primary Completion Date

January 31, 1999

Study Completion Date

June 30, 1999

Conditions
MeaslesMumpsRubellaVaricella
Interventions
BIOLOGICAL

Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live

a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90

BIOLOGICAL

Comparator: Placebo

a single 0.5 mL subcutaneous placebo injection at Day 0

BIOLOGICAL

Comparator: Varivax

a single 0.5 mL subcutaneous injection of Varivax at Day 0

BIOLOGICAL

Comparator: M-M-R II

a single 0.5 mL subcutaneous injection of M-M-R II at Day 0

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00975507 - ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) | Biotech Hunter | Biotech Hunter